BackResmed Overview
Resmed Inc.

Resmed Target Price

Analysts' average 12-month price target for Resmed is $250.

Get informed when a big investor buys or sells

+ Follow

Share Price

$222

Average Target Price

$246.3811% upside

13 analysts in the last 4 months

High: $300 | Low: $213

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-15RBC CapitalCraig Wong-Pan$26218% upsideOpen
2026-08-31KeyBanc$26720.3% upsideOpen
2026-08-19Redburn Partners$2303.6% upsideOpen
2026-08-07Robert W. Baird$2134.1% downsideOpen
2026-08-07KeyBanc$25514.9% upsideOpen
2026-07-21UBSDavid Low$30035.1% upsideOpen
2026-07-16RBC Capital$2345.4% upsideOpen
2026-07-15Mizuho Securities$2200.9% downsideOpen
2026-07-10Jefferies$2251.4% upsideOpen
2026-07-08RBC Capital$27624.3% upsideOpen
2026-07-08Wells Fargo$2251.4% upsideOpen
2026-06-22KeyBanc$26619.8% upsideOpen
2026-06-17Morgan StanleyDavid Bailey$2303.6% upsideOpen
2026-05-01Robert W. Baird$2251.4% upsideOpen
2026-04-27KeyBanc$29030.6% upsideOpen
2026-04-13Evercore ISIAnthony Petrone$25514.9% upsideOpen
2026-01-30RBC CapitalCraig Wong-Pan$31441.4% upsideOpen
2026-01-30Stifel Nicolaus$26519.4% upsideOpen
2026-01-30KeyBancBrett Fishbin$30236% upsideOpen
2026-01-30Robert W. Baird$28126.6% upsideOpen
2026-01-30Piper Sandler$27523.9% upsideOpen
2025-12-18Stifel NicolausJonathan Block$26017.1% upsideOpen
2025-12-16Robert W. Baird$27523.9% upsideOpen
2025-12-12UBSMarcus Curley$34555.4% upsideOpen
2025-11-03Robert W. Baird$30035.1% upsideOpen
2025-10-31KeyBancBrett Fishbin$29934.7% upsideOpen
2025-10-31Morgan StanleyDavid Bailey$30537.4% upsideOpen
2025-10-21Morgan Stanley$30436.9% upsideOpen
2025-10-13Wells Fargo$28026.1% upsideOpen
2025-05-20Morgan StanleyDavid Bailey$28628.8% upsideOpen
2025-04-24KeyBancBrett Fishbin$27423.4% upsideOpen
2025-04-16Mizuho SecuritiesAnthony Petrone$26519.4% upsideOpen
2025-03-05Stifel Nicolaus$2408.1% upsideOpen
2025-01-31Piper SandlerAdam Maeder$26017.1% upsideOpen
2024-12-12Stifel NicolausJonathan Block$25012.6% upsideOpen
2024-10-01RBC CapitalCraig Wong-Pan$2240.9% upsideOpen
2024-09-23Robert W. BairdJoe Vruwink$28026.1% upsideOpen
2024-09-18Wolfe ResearchMike Polark$18018.9% downsideOpen
2024-04-10RBC CapitalCraig Wong-Pan$18715.8% downsideOpen
2024-04-01Stifel NicolausMike Matson$2240.9% upsideOpen
2023-10-27OppenheimerSuraj Kalia$17521.2% downsideOpen
2023-09-06NeedhamMike Matson$18018.9% downsideOpen
2022-06-20RBC CapitalCraig Wong-Pan$2449.9% upsideOpen
2022-04-29RBC Capital$2335% upsideOpen
2021-10-14OppenheimerSuraj Kalia$31240.5% upsideOpen
2021-08-04Morgan StanleySean Laaman$25012.6% upsideOpen
2021-07-28JefferiesAnthony Petrone$2408.1% upsideOpen

Resmed (RMD) FAQ

Resmed (RMD) currently reports a target price of $250. Use the charts on this page to explore Resmed's target price history and peer comparisons.

Analysts' average 12-month price target for Resmed is $250, about 11.0% upside from the current share price of $222.0. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $250, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Resmed, and consider following RMD for alerts when major investors trade the stock.

Resmed is classified in the Healthcare sector. On target price, it currently shows $250. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RMD with unrelated industries.